FDA probing pancreatitis, pre-cancerous findings with GLP-1s, DPP-4s
This article was originally published in Scrip
Executive Summary
Although the details of academic research under examination by the FDA have yet to be published, the data were concerning enough for the agency to warn patients and prescribers about the potential for an increased risk of pancreatitis and pancreatic duct metaplasia, or pre-cancerous cellular changes, in patients with Type II diabetes treated with incretin mimetics, like Amylin's glucagon-like peptide-1 (GLP-1) receptor agonists Byetta (exenatide) and Bydureon (exenatide extended-release) and Merck's dipeptidyl peptidase-4 (DPP-4) inhibitors Januvia (sitagliptin), Janumet (sitagliptin/metformin) and Juvisync (sitagliptin/simvastatin).
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.